NervGen Pharma Corp. announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Dr. Kaye brings over 25 years of industry experience addressing high unmet medical need disease areas. He has significant leadership experience in senior roles where he has provided medical and scientific perspective in clinical development medical affairs. He is currently and has previously served in Chief Medical Officer (CMO) roles overseeing clinical research programs and development, including those with a specific focus on developing novel therapies for central nervous system disorders. Presently, Dr. Kaye is the CMO at Neurana Pharmaceuticals Inc., a Phase 3 company developing a novel treatment for acute and painful muscle spasms.